Medium-Term Bioresorbable Scaffold Outcomes Utilising Data From an Australian Clinical Quality Registry.
Luke P Dawson, Diem Dinh, Stephanie Montalto, Stephen J Duffy, Ronald Dick, Jack Gutman, Angela Brennan, Harriet Carruthers, Janine Doyle, Dion Stub, Robert Whitbourn, Nicholas Cox, Jennifer Cooke, Robert Gooley, Chin Hiew, Christopher Reid, Jeffrey Lefkovits, undefined Victorian Cardiac Outcomes Registry
Heart Lung and Circulation | Published : 2020
BACKGROUND: Bioresorbable scaffolds (BRS) are a novel technology in coronary intervention. However, recent trials demonstrate higher rates of device failure compared to contemporary drug-eluting stents. This study sought to utilise a clinical quality registry to assess the medium-term safety of the Abbott Absorb BRS (Abbott Vascular, Santa Clara, CA, USA), in an Australian context. METHODS: A prospective, observational study of 192 BRS percutaneous coronary interventions (PCI) compared to 31,773 non-BRS PCIs entered in the Victorian Cardiac Outcomes Registry from 2013 to 2017. The main outcome measure was patient-oriented composite endpoint (POCE) events comprising all-cause mortality, any m..View full abstract